Sagimet Biosciences Inc. Operating Expenses
Sagimet Biosciences Inc. (SGMT) reported Operating Expenses of $15.82 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- Sagimet Biosciences Inc. operating expenses for the quarter ending 2026-06-30 was $15.82M, a 32.65% increase year-over-year.
- Sagimet Biosciences Inc. operating expenses for the quarter ending 2026-03-31 was $11.71M, a 41.04% decline year-over-year.
- Sagimet Biosciences Inc. operating expenses for the quarter ending 2025-12-31 was $10.77M, a 40.84% decline year-over-year.
- Sagimet Biosciences Inc. operating expenses for the quarter ending 2025-09-30 was $14.33M, a 15.19% decline year-over-year.
- Sagimet Biosciences Inc. operating expenses for fiscal 2025 was $56.89M, a 4.47% increase from fiscal 2024.
- Sagimet Biosciences Inc. operating expenses for fiscal 2024 was $54.45M, a 66.32% increase from fiscal 2023.
- Sagimet Biosciences Inc. operating expenses for fiscal 2023 was $32.74M, a 5.43% increase from fiscal 2022.
- Sagimet Biosciences Inc. operating expenses for fiscal 2022 was $31.05M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.82M 10-Q · filed 2026-08-11 | $27.53M 10-Q · filed 2026-08-11 | $38.30M derived: sum of 3 quarters · filed 2026-08-11 | $52.63M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $11.71M 10-Q · filed 2026-05-12 | $22.48M derived: sum of 2 quarters · filed 2026-05-12 | $36.81M derived: sum of 3 quarters · filed 2026-05-12 | $48.74M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $10.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $25.10M derived: sum of 2 quarters · filed 2026-03-11 | $37.02M derived: sum of 3 quarters · filed 2026-08-11 | $56.89M 10-K · filed 2026-03-11 |
| 2025-09-30 | $14.33M 10-Q · filed 2025-11-13 | $26.26M derived: sum of 2 quarters · filed 2026-08-11 | $46.12M 10-Q · filed 2025-11-13 | $64.32M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $11.93M 10-Q · filed 2026-08-11 | $31.79M 10-Q · filed 2026-08-11 | $49.98M derived: sum of 3 quarters · filed 2026-08-11 | $66.89M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $19.86M 10-Q · filed 2026-05-12 | $38.06M derived: sum of 2 quarters · filed 2026-05-12 | $54.96M derived: sum of 3 quarters · filed 2026-05-12 | $65.55M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $18.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $35.10M derived: sum of 2 quarters · filed 2026-03-11 | $45.69M derived: sum of 3 quarters · filed 2026-03-11 | $54.45M 10-K · filed 2026-03-11 |
| 2024-09-30 | $16.90M 10-Q · filed 2025-11-13 | $27.49M derived: sum of 2 quarters · filed 2025-11-13 | $36.26M 10-Q · filed 2025-11-13 | $45.73M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $10.59M 10-Q · filed 2025-08-13 | $19.36M 10-Q · filed 2025-08-13 | $28.82M derived: sum of 3 quarters · filed 2025-08-13 | $38.27M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $8.77M 10-Q · filed 2025-05-08 | $18.23M derived: sum of 2 quarters · filed 2025-05-08 | $27.69M derived: sum of 3 quarters · filed 2025-05-08 | $34.74M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $9.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $18.92M derived: sum of 2 quarters · filed 2025-03-12 | $25.98M derived: sum of 3 quarters · filed 2025-03-12 | $32.74M 10-K · filed 2025-03-12 |
| 2023-09-30 | $9.45M 10-Q · filed 2024-11-14 | $16.51M derived: sum of 2 quarters · filed 2024-11-14 | $23.27M 10-Q · filed 2024-11-14 | $30.66M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $7.06M 10-Q · filed 2024-08-14 | $13.82M 10-Q · filed 2024-08-14 | $21.21M derived: sum of 3 quarters · filed 2024-08-14 | $28.90M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $6.76M 10-Q · filed 2024-05-15 | $14.15M derived: sum of 2 quarters · filed 2024-05-15 | $21.84M derived: sum of 3 quarters · filed 2024-05-15 | $29.08M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $7.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $15.07M derived: sum of 2 quarters · filed 2024-03-25 | $22.31M derived: sum of 3 quarters · filed 2024-03-25 | $31.05M 10-K · filed 2024-03-25 |
| 2022-09-30 | $7.69M 10-Q · filed 2023-11-13 | $14.92M derived: sum of 2 quarters · filed 2023-11-13 | $23.67M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $7.24M 10-Q · filed 2023-08-21 | $15.98M 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |